Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890236 | 0.83 | TSHR (0.47) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL755732 | 0.83 | ALDH1A1 (0.47) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL19578000 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL13747766 | 0.81 | TSHR (0.46) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL888725 | 0.80 | CYP3A4 (0.46) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL14665155 | 0.79 | ALDH1A1 (0.64) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL8907264 | 0.79 | CYP2C19 (0.59) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL28762519 | 0.78 | ALDH1A1 (0.62) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL10501886 | 0.78 | ALDH1A1 (0.57) | ALDH1A1CYP1A2TSHRCYP2C19KCNA5 | |
| SCHEMBL8921081 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP1A2KCNH2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 229/4885CYP1A2 240/4885TSHR 4689/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885CYP1A2 390/4885TSHR 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.